Form 8-K PTC THERAPEUTICS, INC. For: Sep 15
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
PTC Therapeutics (PTCT) PT Lowered to $45 at Truist Securities; 'PTC isn't dead'
September 18, 2023 6:14 AM EDTTruist Securities analyst Robyn Karnauskas lowered the price target on PTC Therapeutics (NASDAQ: PTCT) to $45.00 (from $60.00) while maintaining a Buy rating.
THE analyst commented, "In addition to the negative CHMP decision, we believe concerns about cash position and mgmt's ability to... More
PTC Therapeutics (PTCT) PT Lowered to $53 at JPMorgan, 'Late Stage Assets Remain Significantly Underappreciated'
September 15, 2023 12:50 PM EDTJPMorgan analyst Eric Joseph lowered the price target on PTC Therapeutics (NASDAQ: PTCT) to $53.00 (from $70.00) while maintaining a Overweight rating.
The analyst comments "Were lowering our Dec -24 PT ($53/sh vs $70 prior) but maintaining our Overweight rating following the negative CHMP opinion regarding full / extended conditional marketing authorization... More
